Downgrade Drives Pullback

Citi's sell rating after a 222% rally triggers a near-term valuation reset in Moderna shares. Investors take profits after the sharp move from flu vaccine approval and melanoma vaccine optimism, while the long-term pipeline thesis remains intact.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.